Kempen acted as Joint Bookrunner in the secondary placing of Fagron shares
Placing of 7,184,391 existing ordinary shares representing c. 10% of Fagron’s outstanding share capital by WPEF VI Holdco III BE B.V., jointly owned by Waterland Private Equity Fund VI C.V. and Baltisse NV
Offer price of €16.2 per share, which is a 8.4% discount to the last closing price on 2 July 2019
Gross proceeds amount to c. € 116.4 million
The selling shareholder still holds 20.2% of Fagron’s outstanding share capital post-transaction
Kempen has been actively marketing Fagron via roadshows, investor calls, and our conference
This successful transaction marks Kempen’s seventh Life Sciences ECM transaction in 2019
Fagron is a Belgium based pharmaceuticals company focused on delivering personalised medicine to hospitals, clinics, pharmacies and patients in Europe, North America and Latin America. Fagron covers the entire value chain of personalised medicine including essentials & brands, compounding services, and premium pharmaceuticals.